TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01940653

Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone
Description: Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
Study: NCT03565770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual coaching
Description: coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: completion of the self-assessment test at inclusion, at M6 and M12 for all study participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
Study: NCT01286974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]linifanib
Description: \[14C\]linifanib, single administration, oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869, linifanib
Description: linifanib once a day (QD), oral tablet
Study: NCT03113760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa
Description: Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
Study: NCT01284777

Intervention type: GENETIC
Intervention: blood sample, thoracocentesis
Description: 20ml of blood only one thoracocentesis (the same that one for diagnostic)
Study: NCT00389974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study: NCT00697021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG
Description: Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 100mg and Plavix 75mg
Description: Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
Study: NCT02451904

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation
Study: NCT04716140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement of the MTP1 cartillage lesion and microfracture
Description: Patients with a MTP1 cartillage lesion \> grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
Study: NCT03262337

Intervention type: OTHER
Intervention: none, this is an observational study
Description: none, this is an observational study

Intervention type: OTHER
Intervention: none, this is an observational study
Description: none, this is an observational study

Intervention type: OTHER
Intervention: none, this is an observational study
Description: none, this is an observational study
Study: NCT04003311

Intervention type: DEVICE
Intervention: Comprehensive Primary Micro Stem
Description: Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.

Intervention type: DEVICE
Intervention: Comprehensive Anatomic Versa-Dial Titanium Humeral Head
Description: Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
Study: NCT02728921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Albumin infusion 30 min
Description: Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Albumin infusion 3 hours
Description: Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
Study: NCT03544528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration
Description: Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
Study: NCT02406014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate Gel, 0.015%
Description: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium gel 3%
Description: Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
Study: NCT03029780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opdivo
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opdivo
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yervoy
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yervoy
Description: Specified dose on specified days
Study: NCT01015261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Allogenic Bone Marrow Transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1. Cyclophosphamide 1200 mg/m2 D15~2. Daunorubicin 45 mg/m2 D15-D18~3. Vincristine 1 mg/m2 D15, D22~4. Dexamethasone 24 mg/d D12-D28
Study: NCT04487847

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007 PET/CT
Description: 18F-PSMA-1007 PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007 PET/CT
Description: 18F-PSMA-1007 PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007 PET/CT
Description: 18F-PSMA-1007 PET/CT
Study: NCT03391713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Poster
Description: The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
Study: NCT01754779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets twice daily of matching placebo during the placebo phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets twice daily of matching placebo during the placebo phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets twice daily of matching placebo during the placebo phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets twice daily of matching placebo during the placebo phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets twice daily of matching placebo during the placebo phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets twice daily of matching placebo during the placebo phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citric Acid
Description: 3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citric Acid
Description: 3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citric Acid
Description: 3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citric Acid
Description: 3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citric Acid
Description: 3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citric Acid
Description: 3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: 2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)
Study: NCT01261767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for subcutaneous (under the skin) injection
Study: NCT01592240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Placebo Q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg PF-04950615 (RN316)
Description: PF-04950615 200 mg, Q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg PF-04950615 (RN316)
Description: PF-04950615 300 mg, Q28d
Study: NCT00593112

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02152423

Intervention type: DRUG
Group type: OTHER
Intervention: LOVENOX
Description: LMWH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENOXAMED
Description: LMWH
Study: NCT03893929

Intervention type: DIAGNOSTIC_TEST
Intervention: New Biological markers for prostate cancer diagnosis and management
Description: To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
Study: NCT02517515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
Study: NCT03453463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 3x week predominately resistance exercise for 18 months
Study: NCT00636623

Intervention type: OTHER
Group type: OTHER
Intervention: Pilates exercises
Description: 15 FM patients participated in the PE programme three times a week during a 4-week period
Study: NCT01754779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: 2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: 2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: 2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: 2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: 2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)
Study: NCT02639026

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: 20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: 20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 1 mg/kg every 4 weeks for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 1 mg/kg every 4 weeks for 4 doses
Study: NCT02206152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01560377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT Endoscopic Fluorescence Imaging System
Description: The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
Study: NCT04506580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture
Description: DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
Study: NCT01227564

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Phosphate buffered saline (PBS)
Description: Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
Study: NCT05193357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based intermittent pneumatic compression (IPC) device
Description: During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
Study: NCT04256889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nfant(R) feeding system
Description: Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
Study: NCT00610584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: minimal (sham)acupuncture
Description: arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
Study: NCT03047603

Intervention type: DIAGNOSTIC_TEST
Intervention: PIVKA-II
Description: Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: PIVKA-II
Description: Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: PIVKA-II
Description: Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: PIVKA-II
Description: Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
Study: NCT01207934

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose leptin
Description: 30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose leptin
Description: 80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
Study: NCT00636623

Intervention type: OTHER
Group type: OTHER
Intervention: Connective tissue massage
Description: 21 patients received CTM, three times a week during a 4-week period
Study: NCT04142463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care pathway
Description: A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
Study: NCT04102540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infographic intervention
Description: Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
Study: NCT00932490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Coaching
Description: Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
Study: NCT01611103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
Study: NCT01443429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beraprost sodium(BPS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beraprost sodium(BPS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beraprost sodium(BPS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beraprost sodium(BPS)
Study: NCT00074763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
Study: NCT00649974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride Tablets 1000 mg
Description: 1000mg, single dose fasting
Study: NCT04291300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177-PSMA-I&T
Description: 4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
Study: NCT00818038

Intervention type: DRUG
Intervention: BG0002 (natalizumab)
Description: Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.